标题
Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 14, Issue 8, Pages 15885-15909
出版商
MDPI AG
发表日期
2013-07-30
DOI
10.3390/ijms140815885
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antiangiogenic Therapies in Epithelial Ovarian Cancer
- (2017) Deanna G. K. Teoh et al. Cancer Control
- Angiogenesis Inhibitors in the Treatment of Epithelial Ovarian Cancer
- (2013) Ernest S. Han et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
- (2013) Tina Sharma et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- breast cancer, early stage
- (2012) T. S. K. Mok et al. ANNALS OF ONCOLOGY
- Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
- (2012) G Freyer et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Role of angiogenesis in the pathogenesis of cancer
- (2012) Paulo M. Hoff et al. CANCER TREATMENT REVIEWS
- Anti-Angiogenic Approaches to Malignant Gliomas
- (2012) R. Soffietti et al. CURRENT CANCER DRUG TARGETS
- Novel targets for VEGF-independent anti-angiogenic drugs
- (2012) Marco Petrillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer
- (2012) Teresa Troiani et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cediranib: a VEGF receptor tyrosine kinase inhibitor
- (2012) Marina Sahade et al. Future Oncology
- Ovarian low-grade serous carcinoma: A comprehensive update
- (2012) Ivan Diaz-Padilla et al. GYNECOLOGIC ONCOLOGY
- A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma
- (2012) Susana M. Campos et al. GYNECOLOGIC ONCOLOGY
- Clinical trials and future potential of targeted therapy for ovarian cancer
- (2012) Hiroaki Itamochi et al. International Journal of Clinical Oncology
- Antiangiogenic Agents in Combination With Chemotherapy for the Treatment of Epithelial Ovarian Cancer
- (2012) Deanna Teoh et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting angiogenesis in the pathological ovary
- (2012) W. Colin Duncan et al. REPRODUCTION FERTILITY AND DEVELOPMENT
- Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer
- (2011) Kathryn F. McGonigle et al. CANCER
- Bevacizumab and ovarian cancer
- (2011) Shinya Sato et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- The role of targeted therapy in ovarian cancer
- (2011) Susana Banerjee et al. EUROPEAN JOURNAL OF CANCER
- Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
- (2011) Kazuya Kudoh et al. GYNECOLOGIC ONCOLOGY
- Overview of anti-angiogenic agents in development for ovarian cancer
- (2011) Robert A. Burger GYNECOLOGIC ONCOLOGY
- Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer
- (2011) Bengt Sorbe et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
- (2011) Robert L Coleman et al. LANCET ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines
- (2011) R Grepin et al. ONCOGENE
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
- (2010) Robert J. Kurman et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma
- (2010) Hanan AlSaeid Alshenawy Annals of Diagnostic Pathology
- Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma
- (2010) Aref Agheli et al. ANTI-CANCER DRUGS
- Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling
- (2010) Noriomi Matsumura et al. CANCER SCIENCE
- VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis
- (2010) Luqing Zhang et al. CELL RESEARCH
- Lymphangiogenesis and cancer metastasis
- (2010) Mahir et al. Frontiers in Bioscience-Landmark
- FGFR2 mutations are rare across histologic subtypes of ovarian cancer
- (2010) Sara A. Byron et al. GYNECOLOGIC ONCOLOGY
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Angiopoietin-2 Stimulation of Endothelial Cells Induces αvβ3 Integrin Internalization and Degradation
- (2010) Markus Thomas et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
- (2010) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
- (2010) Ahmed Ashour Ahmed et al. JOURNAL OF PATHOLOGY
- Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect
- (2010) Maria Spiliotaki et al. LUNG CANCER
- Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer
- (2010) D. G. Duda et al. ONCOLOGIST
- (Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
- (2010) P. Hamberg et al. ONCOLOGIST
- Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
- (2010) Alfonso Sánchez-Muñoz et al. ONCOLOGY
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
- (2010) Siân Jones et al. SCIENCE
- Contrasting Actions of Selective Inhibitors of Angiopoietin-1 and Angiopoietin-2 on the Normalization of Tumor Blood Vessels
- (2009) Beverly L. Falcón et al. AMERICAN JOURNAL OF PATHOLOGY
- A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
- (2009) A. du Bois et al. ANNALS OF ONCOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas
- (2009) K.-T. Kuo et al. CANCER RESEARCH
- A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
- (2009) A. Gregory Sorensen et al. CANCER RESEARCH
- The Role of Fibroblast Growth Factors in Tumor Growth
- (2009) M. Korc et al. CURRENT CANCER DRUG TARGETS
- Ovarian carcinoma pathology and genetics: recent advances
- (2009) C. Blake Gilks et al. HUMAN PATHOLOGY
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2009) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)
- (2009) Gerald J. Roth et al. JOURNAL OF MEDICINAL CHEMISTRY
- Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium
- (2009) H. T. Yuan et al. MOLECULAR AND CELLULAR BIOLOGY
- Impact of vessel maturation on antiangiogenic therapy in ovarian cancer
- (2008) Chunhua Lu et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy
- (2008) ELENA FAVARO et al. APMIS
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
- (2008) S. Mabuchi et al. CLINICAL CANCER RESEARCH
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
- Cost of Care for Elderly Cancer Patients in the United States
- (2008) K. Robin Yabroff et al. JNCI-Journal of the National Cancer Institute
- Angiogenesis as a strategic target for ovarian cancer therapy
- (2008) Whitney A Spannuth et al. Nature clinical practice. Oncology
- Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting
- (2008) Kristian Pietras et al. PLOS MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started